Outcomes in Young Women With Breast Cancer of Triple-Negative Phenotype: The Prognostic Significance of CK19 Expression

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 1, 2008, Pages 35-42

  Parikh, Rahul R ^a   Yang, Qifeng ^a   Higgins, Susan A ^b   Haffty, Bruce G ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Local recurrence; Molecular markers; Triple negative

Indexed keywords

BIOMARKERS; GENE EXPRESSION; MICROARRAYS; ONCOLOGY; PATHOLOGY; RADIOTHERAPY;

BREAST CANCER; LOCAL RECURRENCE; MOLECULAR MARKERS; MULTIVARIATE MODELS;

TUMORS;

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHENOTYPE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TISSUE MICROARRAY;

ADULT; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KERATIN-19; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37049039675     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.066     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Brenton J.D., Carey L.A., Ahmed A.A., et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?. J Clin Oncol 23 (2005) 7350-7360
3. Jacquemier J., Ginestier C., Rougemont J., et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65 (2005) 767-779
4. Bonnier P., Romain S., Charpin C., et al. Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. Int J Cancer 62 (1995) 138-144
5. Chung M., Chang H.R., Bland K.I., et al. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77 (1996) 97-103
6. Fowble B.L., Schultz D.J., Overmoyer B., et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 30 (1994) 23-33
7. Harrold E.V., Turner B.C., Matloff E.T., et al. Local recurrence in the conservatively treated breast cancer patient: A correlation with age and family history. Cancer J Sci Am 4 (1998) 302-307
8. Borger J., Kemperman H., Hart A., et al. Risk factors in breast-conservation therapy. J Clin Oncol 12 (1994) 653-660
9. Park C.C., Mitsumori M., Nixon A., et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 18 (2000) 1668-1675
10. Voogd A.C., Peterse J.L., Crommelin M.A., et al. Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST). Eur J Cancer 35 (1999) 1828-1837
11. Vrieling C., Collette L., Fourquet A., et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer 39 (2003) 932-944
12. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
13. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
14. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10 (2004) 5367-5374
15. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24 (2006) 5652-5657
16. van de Rijn M., Perou C.M., Tibshirani R., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161 (2002) 1991-1996
17. Matos I., Dufloth R., Alvarenga M., et al. p63, Cytokeratin 5, and P-cadherin: Three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447 (2005) 688-694
18. Kusinska R., Potemski P., Jesionek-Kupnicka D., et al. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma-relation with grade, stage, estrogen receptor and HER2. Pol J Pathol 56 (2005) 107-110
19. Korsching E., Packeisen J., Agelopoulos K., et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82 (2002) 1525-1533
20. Abd El-Rehim D.M., Pinder S.E., Paish C.E., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203 (2004) 661-671
21. Foulkes W.D., Stefansson I.M., Chappuis P.O., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95 (2003) 1482-1485
22. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418-8423
23. Turner N., Tutt A., and Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 4 (2004) 814-819
24. Rimm D.L., Camp R.L., Charette L.A., et al. Tissue microarray: A new technology for amplification of tissue resources. Cancer J 7 (2001) 24-31
25. Vicini F.A., Kestin L., Chen P., et al. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst 95 (2003) 1205-1210
26. Jourdan F., Sebbagh N., Comperat E., et al. Tissue microarray technology: Validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443 (2003) 115-121
27. Leversha M.A., Fielding P., Watson S., et al. Expression of p53, pRB, and p16 in lung tumours: A validation study on tissue microarrays. J Pathol 200 (2003) 610-619
28. Charafe-Jauffret E., Ginestier C., Monville F., et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25 (2006) 2273-2284
29. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
30. Gusterson B.A., Ross D.T., Heath V.J., et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7 (2005) 143-148
31. Lacroix M., and Leclercq G. The "portrait" of hereditary breast cancer. Breast Cancer Res Treat 89 (2005) 297-304
32. Turner B.C., Gumbs A.A., Carter D., et al. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. Int J Radiat Oncol Biol Phys 47 (2000) 1169-1176
33. Mansfield C.M., Komarnicky L.T., Schwartz G.F., et al. Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy. Cancer 75 (1995) 2328-2336
34. Mansour E.G., Ravdin P.M., and Dressler L. Prognostic factors in early breast carcinoma. Cancer 74 (1994) 381-400
35. Potemski P., Kusinska R., Watala C., et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69 (2005) 478-485
36. Livasy C.A., Karaca G., Nanda R., et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19 (2006) 264-271
37. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
38. Moulder S.L., Yakes F.M., Muthuswamy S.K., et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61 (2001) 8887-8895